Additionally, M3S-GRPred was applied to identify potential GR antagonists among FDA-approved drugs confirmed through molecular docking, followed by detailed MD simulation studies for drug repurposing in Cushing’s syndrome. The gene discussed is NR3C1; the disease is Cushing syndrome.